• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
The influence of treatment on hormone receptor subgroups and breast cancer-specific mortality within US integrated healthcare systems.在美国综合医疗体系中，治疗对激素受体亚组和乳腺癌特异性死亡率的影响。
Cancer Causes Control. 2022 Jul;33(7):1019-1023. doi: 10.1007/s10552-022-01589-4. Epub 2022 May 18.
2
Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.雌激素受体阳性、孕激素受体阴性乳腺癌：与生长因子受体表达及他莫昔芬耐药性的关联
J Natl Cancer Inst. 2005 Sep 7;97(17):1254-61. doi: 10.1093/jnci/dji249.
3
Clinicopathological Characteristics and Breast Cancer-Specific Survival of Patients With Single Hormone Receptor-Positive Breast Cancer.单一激素受体阳性乳腺癌患者的临床病理特征和乳腺癌特异性生存分析。
JAMA Netw Open. 2020 Jan 3;3(1):e1918160. doi: 10.1001/jamanetworkopen.2019.18160.
4
Hormone receptor-negative breast cancer: undertreatment of patients over 80.激素受体阴性乳腺癌：80 岁以上患者治疗不足。
Ann Surg Oncol. 2013 Oct;20(10):3274-8. doi: 10.1245/s10434-013-3115-2. Epub 2013 Jul 10.
5
Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen.雌激素受体阳性、人表皮生长因子受体2阴性乳腺癌的淋巴结转移灶中孕激素受体表达缺失与他莫昔芬治疗后复发相关。
J Clin Pathol. 2017 Nov;70(11):954-960. doi: 10.1136/jclinpath-2016-204304. Epub 2017 Apr 17.
6
Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.单激素受体阳性乳腺癌的预后较差：与三阴性乳腺癌的结局相似。
BMC Cancer. 2015 Mar 18;15:138. doi: 10.1186/s12885-015-1121-4.
7
The combined endocrine receptor in breast cancer, a novel approach to traditional hormone receptor interpretation and a better discriminator of outcome than ER and PR alone.乳腺癌中的联合内分泌受体，一种对传统激素受体解读的新方法，且比单独的雌激素受体（ER）和孕激素受体（PR）更能区分预后。
Br J Cancer. 2016 Oct 11;115(8):967-973. doi: 10.1038/bjc.2016.206. Epub 2016 Sep 22.
8
Negative estrogen receptors and positive progesterone receptors breast cancers.阴性雌激素受体和阳性孕激素受体乳腺癌。
J Gynecol Obstet Hum Reprod. 2021 Feb;50(2):101928. doi: 10.1016/j.jogoh.2020.101928. Epub 2020 Oct 3.
9
Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients.激素受体状态、肿瘤特征与预后：乳腺癌患者的一项前瞻性队列研究
Breast Cancer Res. 2007;9(1):R6. doi: 10.1186/bcr1639.
10
Clinical outcome of adjuvant endocrine treatment according to PR and HER-2 status in early breast cancer.早期乳腺癌中根据孕激素受体（PR）和人表皮生长因子受体2（HER-2）状态进行辅助内分泌治疗的临床结局
Ann Oncol. 2006 Nov;17(11):1631-6. doi: 10.1093/annonc/mdl296. Epub 2006 Sep 15.

引用本文的文献

1
Plasma Protein Binding, Biostability, Metabolite Profiling, and CYP450 Phenotype of TPB15 Across Different Species: A Novel Smoothened Inhibitor for TNBC Therapy.TPB15在不同物种中的血浆蛋白结合、生物稳定性、代谢物谱分析及CYP450表型：一种用于三阴性乳腺癌治疗的新型Smoothened抑制剂
Pharmaceutics. 2025 Mar 26;17(4):423. doi: 10.3390/pharmaceutics17040423.
2
Correction to: The influence of treatment on hormone receptor subgroups and breast cancer-specific mortality within US integrated healthcare systems.对《美国综合医疗系统中治疗对激素受体亚组及乳腺癌特异性死亡率的影响》的更正
Cancer Causes Control. 2023 Jan;34(1):101-102. doi: 10.1007/s10552-022-01627-1.

本文引用的文献

1
Clinicopathological Characteristics and Breast Cancer-Specific Survival of Patients With Single Hormone Receptor-Positive Breast Cancer.单一激素受体阳性乳腺癌患者的临床病理特征和乳腺癌特异性生存分析。
JAMA Netw Open. 2020 Jan 3;3(1):e1918160. doi: 10.1001/jamanetworkopen.2019.18160.
2
Single Hormone Receptor-Positive Breast Cancer-Signal or Noise?单激素受体阳性乳腺癌——信号还是噪音？
JAMA Netw Open. 2020 Jan 3;3(1):e1918176. doi: 10.1001/jamanetworkopen.2019.18176.
3
Comparison of SEER Treatment Data With Medicare Claims.监测、流行病学与最终结果（SEER）治疗数据与医疗保险理赔数据的比较
Med Care. 2016 Sep;54(9):e55-64. doi: 10.1097/MLR.0000000000000073.
4
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013.个体化治疗早期乳腺癌女性：2013 年圣加仑国际早期乳腺癌专家共识初级治疗要点。
Ann Oncol. 2013 Sep;24(9):2206-23. doi: 10.1093/annonc/mdt303. Epub 2013 Aug 4.
5
Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer.免疫组化定义的 luminal A 型乳腺癌中孕激素受体阳性肿瘤细胞的预后意义。
J Clin Oncol. 2013 Jan 10;31(2):203-9. doi: 10.1200/JCO.2012.43.4134. Epub 2012 Dec 10.
6
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.乳腺癌激素受体及其他因素与辅助他莫昔芬疗效的相关性：随机试验的患者水平荟萃分析。
Lancet. 2011 Aug 27;378(9793):771-84. doi: 10.1016/S0140-6736(11)60993-8. Epub 2011 Jul 28.
7
American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.美国临床肿瘤学会/美国病理学家学会关于乳腺癌雌激素和孕激素受体免疫组织化学检测的指南建议。
J Clin Oncol. 2010 Jun 1;28(16):2784-95. doi: 10.1200/JCO.2009.25.6529. Epub 2010 Apr 19.
8
Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype.具有单一激素受体阳性表型的乳腺癌的生物学和临床特征
J Clin Oncol. 2007 Oct 20;25(30):4772-8. doi: 10.1200/JCO.2007.12.2747. Epub 2007 Sep 17.
9
Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98.在一项比较来曲唑和他莫昔芬辅助治疗绝经后早期乳腺癌的随机试验（BIG 1-98）中，中心评估的雌激素和孕激素受体表达的预后及预测价值
J Clin Oncol. 2007 Sep 1;25(25):3846-52. doi: 10.1200/JCO.2007.11.9453. Epub 2007 Aug 6.
10
Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status.根据雌激素受体、孕激素受体、表皮生长因子受体和人表皮生长因子受体2的状态，原发性乳腺癌患者可从辅助性他莫昔芬治疗中获益。
Ann Oncol. 2006 May;17(5):818-26. doi: 10.1093/annonc/mdl016. Epub 2006 Feb 23.

在美国综合医疗体系中，治疗对激素受体亚组和乳腺癌特异性死亡率的影响。

The influence of treatment on hormone receptor subgroups and breast cancer-specific mortality within US integrated healthcare systems.

机构信息

Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institute of Health, 9609 Medical Center Drive, Bethesda, MD, USA.

Kaiser Permanente Washington Health Research Institute, Kaiser Permanente Washington, Seattle, WA, USA.

出版信息

Cancer Causes Control. 2022 Jul;33(7):1019-1023. doi: 10.1007/s10552-022-01589-4. Epub 2022 May 18.

DOI:10.1007/s10552-022-01589-4
PMID:35583697
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9701354/
Abstract

PURPOSE

Estrogen receptor (ER) + /progesterone receptor (PR) - or ER-/PR + breast cancer prognosis has not been well-described outside of clinical trials. We evaluated the relationship between ER/PR (ER + /PR-, ER-/PR + , ER + /PR + , ER-/PR-) subgroups and breast cancer-specific mortality within a general community setting in the US.

METHODS

A Retrospective cohort of 11,737 women diagnosed with breast cancer between 1990 and 2016 within US integrated healthcare systems (median follow-up = 7 years; 1,104 breast cancer-specific deaths) were included in this analysis. Cox proportional hazards models were used to estimate hazard ratios (HR) and 95% confidence intervals (CI) adjusting for site, demographic and clinicopathological characteristics, and treatment (surgery/radiotherapy, chemotherapy, endocrine therapy).

RESULTS

Breast cancer-specific mortality was higher for those with ER + /PR- (n = 1,233) compared with ER + /PR + tumors (n = 8,439) before (HR = 1.43; 95% CI = 1.17-1.75) and after treatment adjustment (HR = 1.58; 95% CI = 1.27-1.97). ER + /PR- breast cancer-specific mortality remained higher than ER + /PR + tumors when stratified by treatment received. Breast cancer-specific mortality was similar in ER-/PR + (n = 161) compared with ER + /PR + tumors.

CONCLUSION

Our findings suggest that ER + /PR- tumors may have worse breast cancer-specific mortality than ER + /PR + tumors in a community setting.

摘要

目的

雌激素受体（ER）+/孕激素受体（PR）-或 ER-/PR+乳腺癌的预后在临床试验之外的描述并不完善。我们评估了 ER/PR（ER+/PR-、ER-/PR+、ER+/PR+、ER-/PR-）亚组与美国一般社区环境中乳腺癌特异性死亡率之间的关系。

方法

这项回顾性队列研究纳入了 1990 年至 2016 年期间在美国综合医疗保健系统中诊断为乳腺癌的 11737 名女性（中位随访时间为 7 年；1104 例乳腺癌特异性死亡）。使用 Cox 比例风险模型估计风险比（HR）和 95%置信区间（CI），并调整了部位、人口统计学和临床病理特征以及治疗（手术/放疗、化疗、内分泌治疗）。

结果

与 ER+/PR+肿瘤（n=8439）相比，ER+/PR-肿瘤（n=1233）的乳腺癌特异性死亡率更高，治疗前（HR=1.43；95%CI=1.17-1.75）和治疗后调整（HR=1.58；95%CI=1.27-1.97）。当按接受的治疗分层时，ER+/PR-乳腺癌特异性死亡率仍高于 ER+/PR+肿瘤。与 ER+/PR+肿瘤相比，ER-/PR+肿瘤（n=161）的乳腺癌特异性死亡率相似。

结论

我们的研究结果表明，在社区环境中，ER+/PR-肿瘤的乳腺癌特异性死亡率可能比 ER+/PR+肿瘤更差。